No Data
No Data
Allogene Therapeutics(ALLO.US) Director Sells US$42,488.43 in Common Stock
$Allogene Therapeutics(ALLO.US)$ Director MESSEMER DEBORAH M. sold 18,641 shares of common stock on Jun 18, 2024 at an average price of $2.2793 for a total value of $42,488.43.Source: Announcement Wha
Express News | Allogene Therapeutics Inc: Alpha3 Expected to Complete Enrollment in 1H 2026; Bla Submission Anticipated in 2027
Express News | Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (Cema-Cel), an Allogeneic Car T Product, as Part of First Line Treatment for Patients With Large B-Cell Lymphoma (Lbcl) Likely to Relapse
Piper Sandler Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $11
Piper Sandler analyst Biren Amin maintains $Allogene Therapeutics(ALLO.US)$ with a buy rating, and maintains the target price at $11.According to TipRanks data, the analyst has a success rate of 0.0%
Allogene Therapeutics (ALLO) Down 13.9% Since Last Earnings Report: Can It Rebound?
Allogene Therapeutics(ALLO.US) Director Sells US$26,181.12 in Common Stock
$Allogene Therapeutics(ALLO.US)$ Director Humer Franz B sold 11,200 shares of common stock on May 30, 2024 at an average price of $2.3376 for a total value of $26,181.12.Source: Announcement What is s
No Data